You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Retatrutide-Diabetes
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling.
Is retatrutide available in the consumer market?
Retatrutide is a phase 3 investigational agent. Lilly is providing retatrutide only to participants in Lilly‑sponsored clinical trials. At this time, any sale for human use is unlawful.
Is retatrutide being compounded?
According to the U.S. Food and Drug Administration, retatrutide cannot be lawfully compounded.1 Eli Lilly and Company (Lilly) is the only lawful proprietor of retatrutide, which is an investigational molecule. Lilly is only supplying to participants in Lilly-sponsored clinical trials. Any products for sale claiming to be retatrutide are unlawful, may expose patients to potential serious health risks, and should not be taken.
Anyone who believes they received or used retatrutide outside of a Lilly-sponsored clinical trial should contact Lilly via the local customer channels.
For more information on counterfeit or illegally compounded retatrutide, you may visit https://www.lilly.com/safety/real-medicine or contact Lilly at 1-800-LillyRx (1-800-545-5979).2
For information and updates on retatrutide trials please refer to Lilly.com or Clinicaltrials.gov .
References
1FDA's concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration Website. Issued April 4, 2026. Accessed May 6, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
2Protect yourself against counterfeit, fake, and unsafe or untested compounded products. Eli Lilly and Company. Accessed July 17, 2024. https://www.lilly.com/safety/real-medicine
Date of Last Review: April 10, 2026